{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-047433","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.609552+00:00","generated_at":"2026-05-30T00:53:19.251296+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"X4 reports positive Phase 2 mavorixafor data: ANC normalized, G-CSF reduced 70% in chronic neutropenia","bullets":["Mavorixafor monotherapy durably increased mean ANC to normal levels at Month 3 (n=9) and Month 6 (n=8).","Severe CN patients achieved >2-fold mean ANC increase over 6 months (n=4).","G-CSF dose reduced in 9/12 eligible patients; mean reduction 52% at Month 3, 70% at Month 6 with normal ANC.","Neutrophil functionality sub-study: mean % functional neutrophils comparable to healthy donors after 6 months.","No drug-related serious adverse events; mavorixafor generally well tolerated as monotherapy and combination."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-047433","json":"https://secwatch.observer/filing/0001628280-24-047433.json","markdown":"https://secwatch.observer/filing/0001628280-24-047433.md","text":"https://secwatch.observer/filing/0001628280-24-047433.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024047433/0001628280-24-047433-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024047433/xfor-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:53:19.251296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}